JP2011516423A - ウイルス抗原に対する中和分子 - Google Patents

ウイルス抗原に対する中和分子 Download PDF

Info

Publication number
JP2011516423A
JP2011516423A JP2011502108A JP2011502108A JP2011516423A JP 2011516423 A JP2011516423 A JP 2011516423A JP 2011502108 A JP2011502108 A JP 2011502108A JP 2011502108 A JP2011502108 A JP 2011502108A JP 2011516423 A JP2011516423 A JP 2011516423A
Authority
JP
Japan
Prior art keywords
antibody
molecule
sequence
virus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516423A5 (https=
Inventor
ローレンス ホロウィッツ，
ラメシュ アール． バート，
アラン ケー． カシャップ，
Original Assignee
シー レーン バイオテクノロジーズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シー レーン バイオテクノロジーズ， エルエルシー filed Critical シー レーン バイオテクノロジーズ， エルエルシー
Publication of JP2011516423A publication Critical patent/JP2011516423A/ja
Publication of JP2011516423A5 publication Critical patent/JP2011516423A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011502108A 2008-03-28 2009-03-27 ウイルス抗原に対する中和分子 Pending JP2011516423A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4045908P 2008-03-28 2008-03-28
US61/040,459 2008-03-28
PCT/US2009/038636 WO2009121004A2 (en) 2008-03-28 2009-03-27 Neutralizing molecules to viral antigens

Publications (2)

Publication Number Publication Date
JP2011516423A true JP2011516423A (ja) 2011-05-26
JP2011516423A5 JP2011516423A5 (https=) 2013-05-23

Family

ID=41021445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502108A Pending JP2011516423A (ja) 2008-03-28 2009-03-27 ウイルス抗原に対する中和分子

Country Status (8)

Country Link
US (3) US20100040635A1 (https=)
EP (2) EP2274334A2 (https=)
JP (1) JP2011516423A (https=)
CN (1) CN102046656A (https=)
AU (1) AU2009228058A1 (https=)
CA (1) CA2719201A1 (https=)
IL (1) IL208313A0 (https=)
WO (1) WO2009121004A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012526839A (ja) * 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
WO2015025900A1 (ja) * 2013-08-23 2015-02-26 学校法人藤田学園 抗インフルエンザウイルス中和抗体
JP2016094359A (ja) * 2014-11-13 2016-05-26 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
US10214580B2 (en) 2007-03-27 2019-02-26 I2 Pharmaceuticals, Inc. Constructs and libraries comprising antibody surrogate light chain sequences
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
AU2010303568B2 (en) 2009-10-09 2014-07-31 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
WO2011111966A2 (en) * 2010-03-08 2011-09-15 Celltrion, Inc. Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses
EP3248615A1 (en) 2010-03-30 2017-11-29 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
ES2687706T3 (es) * 2010-06-17 2018-10-26 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la gripe
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
EP2640831A1 (en) 2010-11-17 2013-09-25 Sea Lane Biotechnologies,llc. Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
CN107417789A (zh) * 2011-07-18 2017-12-01 生物医学学会 中和抗甲型流感病毒抗体及其用途
EP2748184A1 (en) * 2011-08-27 2014-07-02 Universität Zürich Multi-strain-reactive antibodies for therapy and diagnosis of influenza
IN2014CN02114A (https=) 2011-09-20 2015-05-29 Sinai School Medicine
MX350282B (es) * 2011-09-30 2017-09-01 Celltrion Inc Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
ES2686526T3 (es) 2011-12-05 2018-10-18 Trellis Bioscience, Llc Anticuerpos útiles en la inmunización pasiva contra la influenza
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EA201591164A1 (ru) 2012-12-18 2015-11-30 Икан Скул Оф Медсин Эт Маунт Синай Вакцины против вируса гриппа и их применение
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
US11827693B2 (en) 2013-03-14 2023-11-28 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
CN104045709B (zh) * 2013-08-02 2017-05-24 中国医学科学院病原生物学研究所 人源抗h7n9禽流感病毒中和性抗体a6、其制备方法及应用
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
US20180008702A1 (en) 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
WO2016089181A1 (ko) * 2014-12-05 2016-06-09 (주)셀트리온 1 이상의 인플루엔자 바이러스 중화 결합 분자를 포함하는 애주번트 조성물 및 이를 포함하는 백신 조성물
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3247389A4 (en) 2015-01-23 2019-10-30 Icahn School of Medicine at Mount Sinai INFLUENZAVIRUSSCHUTZIMPFPLÄNE
EA038407B1 (ru) * 2015-02-05 2021-08-24 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
CA3023143A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
CA3052487A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Influenza vaccines based on aav vectors
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
WO2018169785A2 (en) 2017-03-13 2018-09-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Therapeutic antibodies to marburg virus
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
WO2019210144A1 (en) * 2018-04-27 2019-10-31 Vanderbilt University Broadly neutralizing antibodies against hepatitis c virus
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020090747A1 (ja) * 2018-10-29 2020-05-07 株式会社免疫生物研究所 抗ｈｉｖ抗体及びその製造方法
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
WO2023092314A1 (zh) * 2021-11-24 2023-06-01 苏州方科生物科技有限公司 结合bp特异性抗原肽的人源抗体、制备方法及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054882A1 (en) * 1992-09-17 2002-05-09 Yoshinobu Okuno Anti-human influenza virus antibody
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
DD228737A1 (de) * 1984-11-06 1985-10-23 Inst F Angewandte Virologie Verfahren zur herstellung von influenza-inaktivimpfstoffen mit geringer stammabhaengigkeit
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
CA2388054C (en) * 1999-10-18 2012-12-11 Chiron Corporation Compositions and methods for stimulating an immune response against infectious agents
WO2001060402A2 (en) * 2000-02-15 2001-08-23 Intellivax International Inc. Proteosome influenza vaccine
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
DE60328674D1 (de) 2002-04-17 2009-09-17 Bioren Inc Universelle banken für immunoglobuline
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2004254352A1 (en) 2003-06-27 2005-01-13 Roberto Crea Look-through mutagenesis
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
FR2896162B1 (fr) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
CA2675137A1 (en) 2007-01-12 2008-07-24 Sea Lane Biotechnologies, Llc. Combinatorial libraries of conformationally constrained polypeptide sequences
BRPI0809435A2 (pt) * 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
FR2916107B1 (fr) 2007-05-11 2015-11-27 Centre Nat Etd Spatiales Actionneur alternatif a asservissement en boucle fermee
WO2008153236A1 (en) 2007-06-15 2008-12-18 Protheon Co., Ltd An attenuated influenza virus and a live vaccine comprising the same
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054882A1 (en) * 1992-09-17 2002-05-09 Yoshinobu Okuno Anti-human influenza virus antibody
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5011011755; ＳＭＩＲＮＯＶ　Ｙ　Ａ: 'ＡＮ　ＥＰＩＴＯＰＥ　ＳＨＡＲＥＤ　ＢＹ　ＴＨＥ　ＨＥＭＡＧＧＬＵＴＩＮＩＮＳ　ＯＦ　Ｈ１，Ｈ２，Ｈ５，　ＡＮＤ　Ｈ６　ＳＵＢＴＹＰＥＳ　ＯＦ　ＩＮＦＬＵＥＮＺＡ　Ａ　ＶＩＲＵＳ' ＡＣＴＡ　ＶＩＲＯＬＯＧＩＣＡ Ｖ４３　Ｎ４, 19990801, Ｐ２３７-２４４, ＡＣＡＤＥＭＩＡ　ＰＲＡＧＵＥ *
JPN6013050640; Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ ｖｏｌ．６７，　ｎｏ．５, 1993, ｐ．２５５２-２５５８ *
JPN6013050642; Ｐｒｏｃｅｅｄｉｎｇｓ　ｏｆ　ｔｈｅ　Ｎａｔｉｏｎａｌ　Ａｃａｄｅｍｙ　ｏｆ　Ｓｃｉｅｎｃｅｓ ｖｏｌ．１０５，　ｎｏ．３１, 2008, ｐ．１０７５６-１０７６１ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10214580B2 (en) 2007-03-27 2019-02-26 I2 Pharmaceuticals, Inc. Constructs and libraries comprising antibody surrogate light chain sequences
JP2012526839A (ja) * 2009-05-13 2012-11-01 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和分子
US10017561B2 (en) 2009-05-13 2018-07-10 I2 Pharmaceuticals, Inc. Neutralizing molecules to influenza viruses
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
WO2015025900A1 (ja) * 2013-08-23 2015-02-26 学校法人藤田学園 抗インフルエンザウイルス中和抗体
JPWO2015025900A1 (ja) * 2013-08-23 2017-03-02 学校法人藤田学園 抗インフルエンザウイルス中和抗体
JP2016094359A (ja) * 2014-11-13 2016-05-26 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット

Also Published As

Publication number Publication date
US20100040635A1 (en) 2010-02-18
EP2274334A2 (en) 2011-01-19
WO2009121004A3 (en) 2010-03-25
EP2698380A1 (en) 2014-02-19
WO2009121004A2 (en) 2009-10-01
IL208313A0 (en) 2010-12-30
US20120093834A1 (en) 2012-04-19
CA2719201A1 (en) 2009-10-01
AU2009228058A1 (en) 2009-10-01
US9169318B2 (en) 2015-10-27
CN102046656A (zh) 2011-05-04
US20170136118A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
US9169318B2 (en) Neutralizing molecules to viral antigens
AU2016247163B2 (en) Neutralizing molecules to influenza viruses
AU2007249160B2 (en) Neutralizing antibodies to influenza viruses
CA2900712A1 (en) Binding molecule having influenza a virus-neutralizing activity produced from human b cell
US20140199682A1 (en) Influenza neutralizing agents
CN101495511A (zh) 流感病毒的中和抗体
HK1195318A (en) Neutralizing molecules to viral antigens
Paul Characterization and Optimization of Interaction of Monoclonal Antibodies With Influenza a Hemagglutinin
HK1171463A (en) Neutralizing molecules to influenza viruses
HK1133895A (en) Neutralizing antibodies to influenza viruses
HK1192256A (en) Neutralizing antibodies to influenza viruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140502